Voxelotor (Oxbryta®) Withdrawal - NHP Patient Letter

posted 10th October 2024

Posted 3 months ago

By NHP Office

Features New Therapies News & Updates Patient Guidelines Publications
Voxelotor (Oxbryta®) Withdrawal - NHP Patient Letter

Following the unforeseen Pfizer withdrawal of Voxelotor (Oxbryta®) Medication for Sickle Cell Disease on 25th September 2024, the NHP provided a letter to assist affected Sickle Cell Disorder patients. This letter is based on the limited information available by the company and the panel anticipates further information and guidance from the company.